🌿 Environment 1d ago · Ben Fidler

FDA scientists question Capricor data; Legend CEO steps down

BioPharma Dive
BioPharma industry news
View Channel →
FDA scientists question Capricor data; Legend CEO steps down
Source ↗ 👁 0 💬 0
Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipeline trouble.

Comments (0)

Sign in to join the discussion

More Like This

‘Back on track’: Centene swings to more than $1B in profit in Q2
Healthcare Dive - Latest News · 8h ago
GSK prepares for patent cliff with $2.5B cost-cutting plan
BioPharma Dive - Latest News · 8h ago
Behind the New York data center pause is legislation that could impact existing facilities
Utility Dive - Latest News · 8h ago
📰
Momentum Environmental acquires firm to expand industrial waste platform
Waste Dive - Latest News · 9h ago
HUD funding changes spur lawsuit from fair housing groups
Smart Cities Dive - Latest News · 9h ago
Boston Scientific to restructure, taking up to $800M in charges
MedTech Dive - Latest News · 9h ago